Neil Ahluwalia
Vertex Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Cystic Fibrosis Research Advances, Nematode management and characterization studies, Neonatal Respiratory Health Research, Pediatric health and respiratory diseases, Asthma and respiratory diseases
Most-Cited Works
- → Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial(2019)1,322 cited
- → Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells(2006)283 cited
- → A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele(2021)272 cited
- → Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes(2021)263 cited
- → New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses(2014)230 cited
- → ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis(2017)166 cited
- → Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions(2009)157 cited
- → Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study(2022)129 cited
- → Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele(2023)119 cited
- → Interferon-γ and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm Formation and Rupture(2009)119 cited